Cancer NetworkOriginal article
<![CDATA[Sirexatamab Regimen May Improve PFS, OS in DKK1-High Colorectal Cancer]]>
Data ReadoutpositivesirexatamabPositive
AI Analysis
Summary
Final DeFianCe trial results demonstrate that sirexatamab improves progression-free survival and overall survival in DKK1-high second-line colorectal cancer patients, with baseline plasma DKK1 levels predicting treatment benefit.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Final DeFianCe trial results showed baseline plasma DKK1 predicts deepening sirexatamab benefit in second-line colorectal cancer with potential improvements in PFS and OS
Importance:7/10
Sentiment:
0.70
colorectal cancerDKK1phase 3 dataprogression-free survivaloverall survivalbiomarker
Related Companies
Read the original article
Published by Cancer Network on August 12, 2026 3:59 PM